Padrón, Lacey J. http://orcid.org/0000-0003-0064-5565
Maurer, Deena M.
O’Hara, Mark H.
O’Reilly, Eileen M. http://orcid.org/0000-0002-8076-9199
Wolff, Robert A.
Wainberg, Zev A.
Ko, Andrew H.
Fisher, George
Rahma, Osama
Lyman, Jaclyn P.
Cabanski, Christopher R.
Yu, Jia Xin
Pfeiffer, Shannon M.
Spasic, Marko
Xu, Jingying
Gherardini, Pier Federico
Karakunnel, Joyson
Mick, Rosemarie
Alanio, Cécile
Byrne, Katelyn T.
Hollmann, Travis J. http://orcid.org/0000-0003-1599-0433
Moore, Jonni S. http://orcid.org/0000-0002-2975-336X
Jones, Derek D.
Tognetti, Marco http://orcid.org/0000-0002-2379-1525
Chen, Richard O. http://orcid.org/0000-0002-2842-4476
Yang, Xiaodong
Salvador, Lisa
Wherry, E. John http://orcid.org/0000-0003-0477-1956
Dugan, Ute
O’Donnell-Tormey, Jill
Butterfield, Lisa H. http://orcid.org/0000-0002-3439-9844
Hubbard-Lucey, Vanessa M.
Ibrahim, Ramy
Fairchild, Justin
Bucktrout, Samantha
LaVallee, Theresa M.
Vonderheide, Robert H. http://orcid.org/0000-0002-7252-954X
Article History
Received: 20 December 2021
Accepted: 15 April 2022
First Online: 3 June 2022
Change Date: 21 July 2022
Change Type: Update
Change Details: In the version of this article initially published, the Supplementary information file was missing Supplementary Tables 1–14, Clinical Study Protocol and Statistical Analysis Plan, which have now been restored in the online version of the article.
Competing interests
: A.H.K., E.M.O., R.H.V., M.H.O., G.F. and E.J.W. report grants from the Parker Institute for Cancer Immunotherapy (PICI) during the conduct of this study. A.H.K. reports grants from Celgene, Apexigen and Bristol Myers Squibb (BMS) outside the submitted work. E.M.O. reports research funding from MSK, Genentech/Roche, Celgene/BMS, BioNTech, AstraZeneca, Arcus and Elicio and consulting/DSMB for Cytomx Therapeutics, Rafael Therapeutics, Silenseed, Tyme, Seagen, Boehringer Ingelheim, BioNTech, Ipsen, Merck, IDEAYA, AstraZeneca, Noxxon, BioSapien, Cend Therapeutics, Thetis, Bayer (spouse), Genentech/Roche (spouse), Celgene/BMS (spouse) and Eisai (spouse). L.H.B. declares the following unrelated advisory activities: StemImmune/Calidi, Western Oncolytics, Torque Therapeutics, Khloris, Pyxis, Cytomix, DCprime, RAPT, Takeda and EnaraBio. O.R. reports personal fees from Merck, Celgene, Five Prime Therapeutics, GlaxoSmithKline, Bayer, Roche/Genentech, Puretech, Imvax and Sobi outside the submitted work and has a patent pending for methods that make use of pembrolizumab and trebananib. P.F.G. reports stock ownership in Teiko.bio. R.H.V. reports grants from FibroGen, Inovio, Janssen and Eli Lilly and personal fees from MedImmune, Eli Lilly, Celgene, Celldex Therapeutics and Verastem Oncology outside the submitted work; is an inventor on a licensed patent relating to cancer cellular immunotherapy and cancer vaccines; and receives royalties from Children’s Hospital Boston for a licensed research-only monoclonal antibody. R.O.C. is an employee of Personalis, a company that PICI paid to produce sequence information for some samples reported in this paper as part of a collaboration. R.O.C. is also an inventor on US patent number 09183496 issued to Personalis, which describes the genomic analyses in the Personalis sequencing platform used to sequence the samples in this study. T.M.L. reports Coherus Biosciences employment; LISCure Biosciences Scientific Advisory Board membership; stock ownership in AstraZenca; and consulting outside the submitted work for Grey Wolf Therapeutics and BiOneCure. V.M.H.-L. is an employee of BMS and holds stock. Z.A.W. reports grants from Novartis, Five Prime Therapeutics, Plexxikon and BMS and personal fees from Merck, Eli Lilly, Daiichi, AstraZeneca and Bayer outside the submitted work. M.S. reports consulting for Natera. M.H.O. reports grants from BMS and Celldex; grants and non-financial support from Stand Up To Cancer; and personal fees from Natera outside the submitted work. M.T. is an employee of Biognosys AG. G.F. reports personal fees from Merck, Roche/Genentech and CytomX outside the submitted work; and his spouse owns stock in Seattle Genetics. E.J.W. is a consultant or an advisor for Merck, Elstar, Janssen, Related Sciences, Synthekine and Surface Oncology; is a founder of Surface Oncology and Arsenal Biosciences; and is an inventor on US patent number 10,370,446, submitted by Emory University that covers the use of PD-1 blockade to treat infections and cancer. L.J.P., D.M.M., R.A.W., J.P.L., C.R.C., J.X.Y., S.M.P., J.X., J.K., R.M., C.A., K.T.B., T.J.H., J.S.M., D.D.J., X.Y., L.S., U.D., J.O.-T., R.I., J.F. and S.B. report no competing interests related to the work presented.